NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented
Policy / Regulatory

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

China's National Medical Products Administration (NMPA) released the 109th Catalog of Reference Listed Drugs for Chemical Generic Drugs, adding 30 new product specifications and supplementing information for 24 product specifications…

Merck's KEYTRUDA (Pembrolizumab) Wins NMPA Approval in Early‑Stage High‑Risk TNBC – Label Expansion Beyond PD‑L1 CPS ≥ 20 for China's Only Approved PD‑1 Perioperative Breast Cancer Therapy
CompanyDrug

Merck’s KEYTRUDA (Pembrolizumab) Wins NMPA Approval in Early‑Stage High‑Risk TNBC – Label Expansion Beyond PD‑L1 CPS ≥ 20 for China’s Only Approved PD‑1 Perioperative Breast Cancer Therapy

Novo Nordisk's Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China's Broadest‑Label Long‑Acting Growth Hormone
CompanyDrug

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

NMPA Approves Expanded Indication for Merck's Winrevair (Sotatercept) – First‑in‑Class Activin Signaling Inhibitor Now Covers WHO Functional Class II–IV PAH in China
CompanyDrug

NMPA Approves Expanded Indication for Merck’s Winrevair (Sotatercept) – First‑in‑Class Activin Signaling Inhibitor Now Covers WHO Functional Class II–IV PAH in China

Novo Nordisk's Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
CompanyDrug

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

BioMarin's Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World's Largest Rare Bone Disease Market
CompanyDrug

BioMarin’s Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World’s Largest Rare Bone Disease Market

Hansoh's Selective TYK2 Inhibitor HS‑10374 Hits Co‑Primary Endpoints in Pivotal Phase III Psoriasis Trial – Over Half of Patients Reach PASI 90 at Week 16
CompanyDrug

Hansoh’s Selective TYK2 Inhibitor HS‑10374 Hits Co‑Primary Endpoints in Pivotal Phase III Psoriasis Trial – Over Half of Patients Reach PASI 90 at Week 16

Cutia Therapeutics Secures Macao Marketing Approval for CU‑40102 Topical Finasteride Spray – Completing Greater China Rollout in Androgenetic Alopecia
CompanyDrug

Cutia Therapeutics Secures Macao Marketing Approval for CU‑40102 Topical Finasteride Spray – Completing Greater China Rollout in Androgenetic Alopecia

IMPACT Therapeutics and Pharmanovia Receive Positive CHMP Opinion for Sepalna (Senaparib) – PARP1/2 Inhibitor Set for EU First‑Line Ovarian Cancer Maintenance
CompanyDrug

IMPACT Therapeutics and Pharmanovia Receive Positive CHMP Opinion for Sepalna (Senaparib) – PARP1/2 Inhibitor Set for EU First‑Line Ovarian Cancer Maintenance

Staidson Unit BioJeTay Wins NMPA Trial Acceptance for Bemiltenase alfa in Major Surgical Bleeding – First‑in‑Class Snake Venom–Derived Factor X Activator Expands Beyond Hemophilia
CompanyDrug

Staidson Unit BioJeTay Wins NMPA Trial Acceptance for Bemiltenase alfa in Major Surgical Bleeding – First‑in‑Class Snake Venom–Derived Factor X Activator Expands Beyond Hemophilia

Novo Nordisk Acquires Three Obesity R&D Programs from Kallyope – Non-Incretin Assets Broaden the Cardiometabolic Pipeline Beyond GLP-1

Novo Nordisk Acquires Three Obesity R&D Programs from Kallyope – Non-Incretin Assets Broaden the Cardiometabolic Pipeline Beyond GLP-1

Novo Nordisk A/S (NYSE: NVO) announced that it has acquired three brand‑new obesity research and development programs from New York‑based biotech company Kallyope. Jacob Petersen, head of global research at Novo Nordisk, wrote in a LinkedIn post that one program…

Santo Therapeutics and PolyGene Sign Strategic Partnership – Joint Gene Therapy Delivery Push Targets NF1 Skin Disease

Santo Therapeutics and PolyGene Sign Strategic Partnership – Joint Gene Therapy Delivery Push Targets NF1 Skin Disease

Insilico Medicine Strikes Tens‑of‑Millions‑of‑Dollars AI Collaboration with Frontier Foundation Model Lab – MMAI Gym Framework to Power Generative Biology Models
CompanyDeals

Insilico Medicine Strikes Tens‑of‑Millions‑of‑Dollars AI Collaboration with Frontier Foundation Model Lab – MMAI Gym Framework to Power Generative Biology Models

Qilu Pharmaceutical Drops RMB 400 Million Equity Stake in TYK Medicines – But TY‑9591 Licensing and China Commercialization Deal Stays Alive
CompanyDeals

Qilu Pharmaceutical Drops RMB 400 Million Equity Stake in TYK Medicines – But TY‑9591 Licensing and China Commercialization Deal Stays Alive

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027
CompanyDeals

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027

Orbis Medicines Signs Strategic Collaboration and License Deal with Novo Nordisk – Up to $1.4 Billion to Advance Next-Generation Oral Macrocycle Cardiometabolic Therapies
CompanyDeals

Orbis Medicines Signs Strategic Collaboration and License Deal with Novo Nordisk – Up to $1.4 Billion to Advance Next-Generation Oral Macrocycle Cardiometabolic Therapies

Novo Nordisk's Once-Weekly Sogroya Wins Positive CHMP Opinion for Children with Idiopathic Short Stature – Long-Acting Growth Hormone Set to Expand Beyond GHD in Europe
CompanyDrug

Novo Nordisk’s Once-Weekly Sogroya Wins Positive CHMP Opinion for Children with Idiopathic Short Stature – Long-Acting Growth Hormone Set to Expand Beyond GHD in Europe

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World's First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development
CompanyDeals

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World’s First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development

Medinno Pharmaceutical (Xiamen) Technology Co., Ltd. announced the completion of a Series A financing round exceeding RMB 200 million, led by Sunshine Ronghui Capital, with follow‑on investment from Xiamen Jinyuan…

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status
CompanyDeals

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status

Huadong Medicine's Sinclair Secures Exclusive China Collaboration for Maybio's iPSC‑Engineered MB007 ECM Collagen – Regenerative Aesthetics Bet
CompanyDeals

Huadong Medicine’s Sinclair Secures Exclusive China Collaboration for Maybio’s iPSC‑Engineered MB007 ECM Collagen – Regenerative Aesthetics Bet

WuXi XDC Licenses WuXiTecan‑2 Payload‑Linker Technology to Ona Therapeutics – Exclusive Global ADC Deal Deepens Partnership
CompanyDeals

WuXi XDC Licenses WuXiTecan‑2 Payload‑Linker Technology to Ona Therapeutics – Exclusive Global ADC Deal Deepens Partnership

Dualitas Signs Research Collaboration and License Deal with Roche – Bispecific Antibody Partnership Valued at Up to US$1 Billion
CompanyDeals

Dualitas Signs Research Collaboration and License Deal with Roche – Bispecific Antibody Partnership Valued at Up to US$1 Billion

- Advertisement -
HitGen Co‑Invests in Connexus Therapeutics' Series A – OrbiMed‑Backed Oncology Startup Founded on Phased Technology Licensing
CompanyDeals

HitGen Co‑Invests in Connexus Therapeutics’ Series A – OrbiMed‑Backed Oncology Startup Founded on Phased Technology Licensing

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
CompanyDeals

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

CompanyDeals

HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems
CompanyDeals

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

MIIT and Nine Departments Issue China's "15th Five‑Year Plan for Pharmaceutical Industry Development" – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030
Policy / Regulatory

MIIT and Nine Departments Issue China’s “15th Five‑Year Plan for Pharmaceutical Industry Development” – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030

The Ministry of Industry and Information Technology (MIIT), together with nine other departments, formulated and issued the "15th Five‑Year Plan for Pharmaceutical Industry Development" (the "Plan"), setting quantitative industry targets…

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening
Policy / Regulatory

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

China's NHC Issues Landmark Rare‑Disease Notice – Mandating Province‑Wide Clinics and Quality Control Networks by End‑2026
Policy / Regulatory

China’s NHC Issues Landmark Rare‑Disease Notice – Mandating Province‑Wide Clinics and Quality Control Networks by End‑2026

China's NHSA Pilots Pre-Project Approval System for Medical Service Pricing – Fast Lane for Innovative Technologies
Policy / Regulatory

China’s NHSA Pilots Pre-Project Approval System for Medical Service Pricing – Fast Lane for Innovative Technologies

More News

HemaCell Therapeutics Wins NMPA Clinical Trial Clearance for World's First Stem Cell-Derived Allogeneic Platelet Injection – A Potential Leap Beyond Donor-Dependent Transfusion
Others

HemaCell Therapeutics Wins NMPA Clinical Trial Clearance for World’s First Stem Cell-Derived Allogeneic Platelet Injection – A Potential Leap Beyond Donor-Dependent Transfusion

Alexion's Klygefa Recommended for EU Approval in AChR-Positive Generalized Myasthenia Gravis – AstraZeneca's Subcutaneous Nanobody C5 Inhibitor Clears Major Regulatory Hurdle
CompanyDrug

Alexion’s Klygefa Recommended for EU Approval in AChR-Positive Generalized Myasthenia Gravis – AstraZeneca’s Subcutaneous Nanobody C5 Inhibitor Clears Major Regulatory Hurdle

Novartis' Cosentyx Wins Positive CHMP Opinion for Polymyalgia Rheumatica – IL‑17A Blockade Poised to Enter Steroid-Dependent Rheumatology
CompanyDrug

Novartis’ Cosentyx Wins Positive CHMP Opinion for Polymyalgia Rheumatica – IL‑17A Blockade Poised to Enter Steroid-Dependent Rheumatology

Eli Lilly Wins Full FDA Approval for Inluriyo–Verzenio Combination – Oral Regimen Doubles Median Progression-Free Survival in ESR1-Mutated Metastatic Breast Cancer
CompanyDrug

Eli Lilly Wins Full FDA Approval for Inluriyo–Verzenio Combination – Oral Regimen Doubles Median Progression-Free Survival in ESR1-Mutated Metastatic Breast Cancer

FDA Accepts Alexion's BLA for Efzimfotase Alfa With Priority Review – Potential Twice‑Monthly Enzyme Replacement Therapy for Hypophosphatasia (HPP) Patients Aged 2+
CompanyDrug

FDA Accepts Alexion’s BLA for Efzimfotase Alfa With Priority Review – Potential Twice‑Monthly Enzyme Replacement Therapy for Hypophosphatasia (HPP) Patients Aged 2+

Nuvation Bio Secures FDA sNDA Approval for IBTROZI® (Taletrectinib) – Updated Label Reports Longest Median DOR Among Approved ROS1 TKIs in TKI‑Naïve ROS1‑Positive NSCLC
CompanyDrug

Nuvation Bio Secures FDA sNDA Approval for IBTROZI® (Taletrectinib) – Updated Label Reports Longest Median DOR Among Approved ROS1 TKIs in TKI‑Naïve ROS1‑Positive NSCLC

Roche Opens Genentech Innovation Center Boston at Harvard's Enterprise Research Campus – New US Hub for Cardiovascular, Renal and Metabolism R&D
Company

Roche Opens Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus – New US Hub for Cardiovascular, Renal and Metabolism R&D

TransThera Sciences' YOCHANRA (Tinengotinib) Receives First Prescription in China – World's First Approved Targeted Therapy for Post‑FGFR‑Inhibitor Cholangiocarcinoma
CompanyDrug

TransThera Sciences’ YOCHANRA (Tinengotinib) Receives First Prescription in China – World’s First Approved Targeted Therapy for Post‑FGFR‑Inhibitor Cholangiocarcinoma

Show More